Data compiled by Redley Lamar · ChainSifter Intelligence
1Suppliers
7Customers
3Debt Items
8Related Chains
Source-Backed Evidence Depth
AnaptysBio, Inc. (ANAB) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
12Total relationships
2Distinct source URLs
6High confidence
0.791Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
AnaptysBio, Inc. Suppliers
Ticker
Name
Confidence
Evidence
FIRST-TRACKS-BIOTHERAPEUTICS
FIRST-TRACKS-BIOTHERAPEUTICS
92%
Effective as of the date of the distribution, First Tracks Biotherapeutics, on behalf of itself, grants to AnaptysBio a worldwide, perpetual, irrevocable, fully paid-up, royalty-free, non-transferabl…
AnaptysBio, Inc. Customers
Ticker
Name
Confidence
Evidence
UK-LIMITED
UK-LIMITED
85%
n and Distribution Agreement provides that any and all rights to receive milestone payments under the Vanda License Agreement will be allocated to First Tracks Biotherapeutics. Centessa On November 2…
Reciprocal relationship from TRAX graph: Reciprocal relationship from ANAB graph: Item 1 of this report and with our audited consolidated financial statements and related notes thereto for the year e…
Item 1 of this report and with our audited consolidated financial statements and related notes thereto for the year ended December 31, 2025 included in our Annual Report on Form 10-K. This discussion…
Item 1 of this report and with our audited consolidated financial statements and related notes thereto for the year ended December 31, 2025 included in our Annual Report on Form 10-K. This discussion…
Reciprocal relationship from VNDA graph: Reciprocal relationship from ANAB graph: Reciprocal relationship from VNDA graph: Reciprocal relationship from ANAB graph: Reciprocal relationship from VNDA g…
CAPITAL-RESOURCES
CAPITAL-RESOURCES
62%
for imsidolimab in GPP in February 2026 with a target action date of December 12, 2026. Pursuant to the terms of the Vanda License Agreement, we received an upfront payment of $10.0 million and a $5.…
DELAWARE-GENERAL-CORPORATION
DELAWARE-GENERAL-CORPORATION
62%
collaborators’ or in third party service providers’ operations could result in a material disruption of our drug discovery and development programs. Our system protections may be ineffective or inade…
AnaptysBio, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
ANAB-DEBT-7756
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2017-12-31.
ANAB-DEBT
Debt stack $277.4M
90%
Market cache reports total debt of $277.4M.
ANAB-DEBT-7755
Warrants outstanding: 287
90%
xbrl warrant detail from xbrl 2020-12-31.
AnaptysBio, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for AnaptysBio, Inc..
AnaptysBio, Inc. Ownership
Holder
Name
Confidence
Evidence
ANAB-OWNER-ECOR1-CAPITAL-LLC
EcoR1 Capital, LLC
90%
13F overlay lists EcoR1 Capital, LLC as top holder; 206 tracked holders.
